Guardant Health announces Shield blood-based screening test results

Guardant Health (GH) “announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening for colorectal cancer. Shield is the first and only blood test to receive FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. In the analysis looking at the initial implementation of a blood-based CRC screening test, Shield yielded an adherence rate of 95%. In the first 20,000 patients with a Shield clinical order placed between May 2022 and June 2024 patient adherence far surpassed reported adherence rates for colonoscopy or stool-based tests (25-71%). Median test turnaround time was 15 days from blood sample receipt to a results report.”